Clinical Trial Update: Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study of TRM-1, a TRAIL-R1 monoclonal antibody, in relapsed or refractory non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TRM-1 (TRAIL-R1 monoclonal antibody)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED